Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Fujian Green Pine
300132
5
Yili Chuanning Biotechnology
301301
US OptionsDetailed Quotes
AKBA250516P2500
- 0.05
- 0.000.00%
15min DelayTrading May 13 11:32 ET
0.00High0.00Low
0.00Open0.05Pre Close0 Volume4.45K Open Interest2.50Strike Price0.00Turnover121.52%IV3.73%PremiumMay 16, 2025Expiry Date0.00Intrinsic Value100Multiplier1DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type-0.4038Delta2.3244Gamma50.90Leverage Ratio-0.0453Theta0.0000Rho-20.55Eff Leverage0.0005Vega
Market Insights
Discussing
Trade war escalates: What’s next for Chinese stocks?
🎙️Discussion 1. China-EU EV negotiations kick off recently. How do you think the negotiations will impact the performance of related stocks
Moo Earnings
Feb 17 19:21
Alibaba Q4 FY2024 Earnings Preview: Predict & Win Big! 🚀
Discussing
FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma
Moo Live
Mar 20 02:25
FOMC Press Conference, March 19, 2025
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now
Akebia Therapeutics Stock Discussion
•Revenues: Total revenues were $57.3 million in the first quarter of 2025 as compared to $32.6 million in the first quarter of 2024, driven by initial sales of Vafseo in the U.S. and an increase in sales of Auryxia.
▪Vafseo net product revenues were $12.0 million in the first quarter of 2025. Vafseo was launched into the U.S. market in the first quarter of 2025.
▪Auryxia net product revenues were $43.8 million in the first quarter...
Major Win for Akebia: EMA Committee Recommends Novel Dual-Action Kidney Disease Treatment
Akebia Therapeutics: Ec Will Review Chmp Recommendation, Final Decision Expected in About Two Months
No comment yet